This page collects WhisperX intelligence signals tagged #peptides. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
The U.S. Food and Drug Administration (FDA) is reportedly preparing to grant compounding pharmacies the authority to produce and dispense injectable peptide drugs. This potential policy shift represents a significant regulatory development for a class of substances that has surged in popularity for uses ranging from we...
Robert F. Kennedy Jr., the anti-vaccine activist and Health Secretary, is directly challenging the FDA to reverse its ban on over a dozen injectable peptide treatments. These treatments, which the agency previously restricted for posing significant safety risks, have little to no clinical data supporting their efficacy...
The U.S. Food and Drug Administration is preparing to reverse a significant safety policy, moving to potentially allow compounding pharmacies to produce more than a dozen injectable peptides it had previously banned. These substances, removed from the approved compounding list in 2023, were flagged for 'potentially sig...
Robert F. Kennedy Jr., a prominent voice in wellness circles, is actively promoting the use of experimental peptide drugs, placing him at odds with mainstream public health experts who warn of unstudied risks, including a potential link to cancer. This advocacy marks a sharp departure from his usual emphasis on 'natura...
The FDA is convening a critical advisory panel to reconsider its crackdown on compounded peptides, a move that follows direct public advocacy from presidential candidate Robert F. Kennedy Jr. The July 23-24 meeting will specifically debate whether to add seven peptides back to an approved list for compounding pharmacie...
The FDA is being compelled to reconsider its 2023 ban on a dozen unproven peptides, substances the agency itself flagged as posing significant safety risks. This reversal of regulatory posture is not driven by new scientific data but by direct political pressure from Health Secretary Robert F. Kennedy Jr., a prominent ...